1	Sucralfate	Sucralfate	B-NP	NN	O	0	ROOT
2	in	in	B-PP	IN	O	1	NMOD
3	Helicobacter	Helicobacter	B-NP	NN	O	6	NMOD
4	pylori	pylori	I-NP	NN	O	6	NMOD
5	eradication	eradication	I-NP	NN	O	6	NMOD
6	strategies	strategy	I-NP	NNS	O	2	PMOD
7	.	.	O	.	O	1	P

1	Sucralfate	Sucralfate	B-NP	NN	O	2	NMOD
2	monotherapy	monotherapy	I-NP	NN	O	3	SUB
3	has	have	B-VP	VBZ	O	0	ROOT
4	been	be	I-VP	VBN	O	3	VC
5	shown	show	I-VP	VBN	O	4	VC
6	to	to	I-VP	TO	O	7	VMOD
7	suppress	suppress	I-VP	VB	O	5	VMOD
8	but	but	O	CC	O	7	VMOD
9	not	not	O	RB	O	7	VMOD
10	eradicate	eradicate	B-VP	VB	O	7	VMOD
11	Helicobacter	Helicobacter	B-NP	NN	O	12	NMOD
12	pylori	pylori	I-NP	NN	O	10	OBJ
13	.	.	O	.	O	3	P

1	The	The	B-NP	DT	O	2	NMOD
2	combination	combination	I-NP	NN	O	10	SUB
3	of	of	B-PP	IN	O	2	NMOD
4	sucralfate	sucralfate	B-NP	NN	O	3	PMOD
5	with	with	B-PP	IN	O	4	NMOD
6	antibiotic	antibiotic	B-NP	JJ	O	8	NMOD
7	(	(	I-NP	(	O	8	NMOD
8	s	s	I-NP	NNS	O	5	PMOD
9	)	)	O	)	O	8	NMOD
10	has	have	B-VP	VBZ	O	0	ROOT
11	been	be	I-VP	VBN	O	10	VC
12	evaluated	evaluate	I-VP	VBN	O	11	VC
13	recently	recently	B-ADVP	RB	O	12	VMOD
14	in	in	B-PP	IN	O	12	VMOD
15	the	the	B-NP	DT	O	16	NMOD
16	treatment	treatment	I-NP	NN	O	14	PMOD
17	of	of	B-PP	IN	O	16	NMOD
18	H.	H.	B-NP	NN	O	21	NMOD
19	pylori-positive	pylori-positive	I-NP	JJ	O	21	NMOD
20	duodenal	duodenal	I-NP	JJ	O	21	NMOD
21	ulcer	ulcer	I-NP	NN	O	17	PMOD
22	.	.	O	.	O	10	P

1	The	The	B-NP	DT	O	2	NMOD
2	aim	aim	I-NP	NN	O	6	SUB
3	of	of	B-PP	IN	O	2	NMOD
4	this	this	B-NP	DT	O	5	NMOD
5	article	article	I-NP	NN	O	3	PMOD
6	is	be	B-VP	VBZ	O	0	ROOT
7	to	to	B-VP	TO	O	8	VMOD
8	review	review	I-VP	VB	O	6	PRD
9	the	the	B-NP	DT	O	10	NMOD
10	efficacy	efficacy	I-NP	NN	O	8	OBJ
11	of	of	B-PP	IN	O	10	NMOD
12	sucralfate-containing	sucralfate-containing	B-NP	JJ	O	13	NMOD
13	duotherapy	duotherapy	I-NP	NN	O	16	NMOD
14	and	and	O	CC	O	16	NMOD
15	triple	triple	B-NP	JJ	O	16	NMOD
16	therapy	therapy	I-NP	NN	O	11	PMOD
17	in	in	B-PP	IN	O	16	NMOD
18	duodenal	duodenal	B-NP	JJ	O	20	NMOD
19	ulcer	ulcer	I-NP	NN	O	20	NMOD
20	healing	healing	I-NP	NN	O	25	NMOD
21	and	and	I-NP	CC	O	25	NMOD
22	H.	H.	I-NP	NN	O	25	NMOD
23	pylori	pylori	I-NP	NN	O	25	NMOD
24	eradication	eradication	I-NP	NN	O	25	NMOD
25	rates	rate	I-NP	NNS	O	17	PMOD
26	.	.	O	.	O	6	P

1	Reports	Report	B-NP	NNS	O	0	ROOT
2	on	on	B-PP	IN	O	1	NMOD
3	duotherapy	duotherapy	B-NP	NN	O	6	NMOD
4	and	and	O	CC	O	6	NMOD
5	triple	triple	B-NP	JJ	O	6	NMOD
6	therapy	therapy	I-NP	NN	O	2	PMOD
7	including	include	B-PP	VBG	O	6	NMOD
8	sucralfate	sucralfate	B-NP	NN	O	7	PMOD
9	as	as	B-SBAR	IN	O	8	NMOD
10	the	the	B-NP	DT	O	12	NMOD
11	mediating	mediate	I-NP	VBG	O	12	NMOD
12	agent	agent	I-NP	NN	O	13	SUB
13	were	be	B-VP	VBD	O	9	SBAR
14	analysed	analyse	I-VP	VBN	O	13	VC
15	to	to	B-VP	TO	O	16	VMOD
16	assess	assess	I-VP	VB	O	14	VMOD
17	the	the	B-NP	DT	O	25	NMOD
18	duodenal	duodenal	I-NP	JJ	O	20	NMOD
19	ulcer	ulcer	I-NP	NN	O	20	NMOD
20	healing	healing	I-NP	NN	O	25	NMOD
21	and	and	I-NP	CC	O	25	NMOD
22	H.	H.	I-NP	NN	O	25	NMOD
23	pylori	pylori	I-NP	NN	O	25	NMOD
24	eradication	eradication	I-NP	NN	O	25	NMOD
25	rates	rate	I-NP	NNS	O	16	OBJ
26	.	.	O	.	O	1	P

1	One	One	B-NP	CD	O	2	NMOD
2	study	study	I-NP	NN	O	9	SUB
3	on	on	B-PP	IN	O	2	NMOD
4	duotherapy	duotherapy	B-NP	NN	O	3	PMOD
5	with	with	B-PP	IN	O	4	NMOD
6	sucralfate	sucralfate	B-NP	NN	O	8	NMOD
7	and	and	I-NP	CC	O	8	NMOD
8	amoxycillin	amoxycillin	I-NP	NN	O	5	PMOD
9	achieved	achieve	B-VP	VBD	O	0	ROOT
10	an	an	B-NP	DT	O	13	NMOD
11	ulcer	ulcer	I-NP	NN	O	13	NMOD
12	healing	healing	I-NP	NN	O	13	NMOD
13	rate	rate	I-NP	NN	O	9	OBJ
14	of	of	B-PP	IN	O	13	NMOD
15	86	86	B-NP	CD	O	16	NMOD
16	%	%	I-NP	NN	O	21	NMOD
17	and	and	I-NP	CC	O	21	NMOD
18	H.	H.	I-NP	NN	O	21	NMOD
19	pylori	pylori	I-NP	NN	O	21	NMOD
20	eradication	eradication	I-NP	NN	O	21	NMOD
21	rate	rate	I-NP	NN	O	14	PMOD
22	of	of	B-PP	IN	O	21	NMOD
23	40	40	B-NP	CD	O	24	NMOD
24	%	%	I-NP	NN	O	22	PMOD
25	,	,	O	,	O	9	P
26	which	which	B-NP	WDT	O	9	VMOD
27	compared	compare	B-VP	VBD	O	26	SBAR
28	favourably	favourably	B-ADVP	RB	O	27	VMOD
29	with	with	B-PP	IN	O	27	VMOD
30	sucralfate	sucralfate	B-NP	NN	O	31	NMOD
31	monotherapy	monotherapy	I-NP	NN	O	29	PMOD
32	that	that	B-NP	WDT	O	31	NMOD
33	resulted	result	B-VP	VBD	O	32	SBAR
34	in	in	B-PP	IN	O	33	VMOD
35	duodenal	duodenal	B-NP	JJ	O	37	NMOD
36	ulcer	ulcer	I-NP	NN	O	37	NMOD
37	healing	healing	I-NP	NN	O	42	NMOD
38	and	and	I-NP	CC	O	42	NMOD
39	H.	H.	I-NP	NN	O	42	NMOD
40	pylori	pylori	I-NP	NN	O	42	NMOD
41	eradication	eradication	I-NP	NN	O	42	NMOD
42	rates	rate	I-NP	NNS	O	34	PMOD
43	of	of	B-PP	IN	O	42	NMOD
44	65	65	B-NP	CD	O	45	NMOD
45	%	%	I-NP	NN	O	48	NMOD
46	and	and	O	CC	O	48	NMOD
47	0	0	B-NP	CD	O	48	NMOD
48	%	%	I-NP	NN	O	43	PMOD
49	respectively	respectively	B-ADVP	RB	O	42	NMOD
50	.	.	O	.	O	9	P

1	A	A	B-NP	DT	O	2	NMOD
2	total	total	I-NP	NN	O	6	SUB
3	of	of	B-PP	IN	O	2	NMOD
4	six	six	B-NP	CD	O	5	NMOD
5	studies	study	I-NP	NNS	O	3	PMOD
6	have	have	B-VP	VBP	O	0	ROOT
7	examined	examine	I-VP	VBN	O	6	VC
8	triple	triple	B-NP	JJ	O	9	NMOD
9	therapy	therapy	I-NP	NN	O	7	OBJ
10	using	use	B-VP	VBG	O	9	NMOD
11	sucralfate	sucralfate	B-NP	NN	O	10	OBJ
12	with	with	B-PP	IN	O	10	VMOD
13	two	two	B-NP	CD	O	14	NMOD
14	antibiotics	antibiotic	I-NP	NNS	O	12	PMOD
15	.	.	O	.	O	6	P

1	The	The	B-NP	DT	O	5	NMOD
2	duodenal	duodenal	I-NP	JJ	O	5	NMOD
3	ulcer	ulcer	I-NP	NN	O	5	NMOD
4	healing	healing	I-NP	NN	O	5	NMOD
5	rates	rate	I-NP	NNS	O	6	SUB
6	were	be	B-VP	VBD	O	0	ROOT
7	generally	generally	B-ADVP	RB	O	6	PRD
8	over	over	B-PP	IN	O	7	AMOD
9	90	90	B-NP	CD	O	10	NMOD
10	%	%	I-NP	NN	O	8	PMOD
11	and	and	O	CC	O	16	NMOD
12	the	the	B-NP	DT	O	16	NMOD
13	H.	H.	I-NP	NN	O	16	NMOD
14	pylori	pylori	I-NP	NN	O	16	NMOD
15	eradication	eradication	I-NP	NN	O	16	NMOD
16	rates	rate	I-NP	NNS	O	7	AMOD
17	about	about	B-NP	IN	O	19	NMOD
18	80	80	I-NP	CD	O	17	AMOD
19	%	%	I-NP	NN	O	16	NMOD
20	(	(	O	(	O	27	DEP
21	range	range	B-NP	NN	O	26	NMOD
22	59	59	B-NP	CD	O	26	NMOD
23	%	%	I-NP	NN	O	26	NMOD
24	to	to	I-NP	TO	O	26	NMOD
25	100	100	I-NP	CD	O	26	NMOD
26	%	%	I-NP	NN	O	27	DEP
27	)	)	O	)	O	19	NMOD
28	.	.	O	.	O	6	P

1	In	In	B-PP	IN	O	20	VMOD
2	one	one	B-NP	CD	O	4	NMOD
3	comparative	comparative	I-NP	JJ	O	4	NMOD
4	study	study	I-NP	NN	O	1	PMOD
5	,	,	O	,	O	20	P
6	the	the	B-NP	DT	O	10	NMOD
7	4-week	4-week	I-NP	JJ	O	10	NMOD
8	duodenal	duodenal	I-NP	JJ	O	10	NMOD
9	ulcer	ulcer	I-NP	NN	O	10	NMOD
10	healing	healing	I-NP	NN	O	15	NMOD
11	and	and	I-NP	CC	O	15	NMOD
12	H.	H.	I-NP	NN	O	15	NMOD
13	pylori	pylori	I-NP	NN	O	15	NMOD
14	eradication	eradication	I-NP	NN	O	15	NMOD
15	rates	rate	I-NP	NNS	O	20	SUB
16	of	of	B-PP	IN	O	15	NMOD
17	sucralfate-containing	sucralfate-containing	B-NP	JJ	O	19	NMOD
18	triple	triple	I-NP	JJ	O	19	NMOD
19	therapy	therapy	I-NP	NN	O	16	PMOD
20	were	be	B-VP	VBD	O	0	ROOT
21	not	not	O	RB	O	20	VMOD
22	distinguishable	distinguishable	B-ADJP	JJ	O	20	PRD
23	from	from	B-PP	IN	O	22	AMOD
24	those	those	B-NP	DT	O	23	PMOD
25	of	of	B-PP	IN	O	24	NMOD
26	omeprazole-containing	omeprazole-containing	B-NP	JJ	O	28	NMOD
27	triple	triple	I-NP	JJ	O	28	NMOD
28	therapy	therapy	I-NP	NN	O	25	PMOD
29	.	.	O	.	O	20	P

1	It	It	B-NP	PRP	O	2	SUB
2	is	be	B-VP	VBZ	O	0	ROOT
3	concluded	conclude	I-VP	VBN	O	2	VC
4	that	that	B-SBAR	IN	O	3	VMOD
5	sucralfate	sucralfate	B-NP	NN	O	6	SUB
6	is	be	B-VP	VBZ	O	4	SBAR
7	an	an	B-NP	DT	O	10	NMOD
8	effective	effective	I-NP	JJ	O	10	NMOD
9	mediating	mediate	I-NP	VBG	O	10	NMOD
10	agent	agent	I-NP	NN	O	6	PRD
11	for	for	B-PP	IN	O	10	NMOD
12	the	the	B-NP	DT	O	13	NMOD
13	eradication	eradication	I-NP	NN	O	11	PMOD
14	of	of	B-PP	IN	O	13	NMOD
15	H.	H.	B-NP	NN	O	16	NMOD
16	pylori	pylori	I-NP	NN	O	14	PMOD
17	in	in	B-PP	IN	O	13	NMOD
18	patients	patient	B-NP	NNS	O	17	PMOD
19	with	with	B-PP	IN	O	18	NMOD
20	duodenal	duodenal	B-NP	JJ	O	21	NMOD
21	ulcer	ulcer	I-NP	NN	O	19	PMOD
22	.	.	O	.	O	2	P

